SPINK1 promotes cell growth and metastasis of lung adenocarcinoma and acts as a novel prognostic biomarker |
Xu, Liyun
(Cell and Molecular Biology Laboratory, Affiliated Zhoushan Hospital of Wenzhou Medical University)
Lu, Changchang (Cell and Molecular Biology Laboratory, Affiliated Zhoushan Hospital of Wenzhou Medical University) Huang, Yanyan (Cell and Molecular Biology Laboratory, Affiliated Zhoushan Hospital of Wenzhou Medical University) Zhou, Jihang (Cell and Molecular Biology Laboratory, Affiliated Zhoushan Hospital of Wenzhou Medical University) Wang, Xincheng (Cell and Molecular Biology Laboratory, Affiliated Zhoushan Hospital of Wenzhou Medical University) Liu, Chaowu (Department of Cardio-Thoracic Surgery, Affiliated Zhoushan Hospital of Wenzhou Medical University) Chen, Jun (Department of Cardio-Thoracic Surgery, Affiliated Zhoushan Hospital of Wenzhou Medical University) Le, Hanbo (Department of Cardio-Thoracic Surgery, Affiliated Zhoushan Hospital of Wenzhou Medical University) |
1 | Ying HY, Gong CJ, Feng Y et al (2017) Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway. J Dig Dis 18, 349-358 DOI |
2 | Tania M, Khan MA and Fu J (2014) Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol 35, 7335-7342 DOI |
3 | Chakraborti S, Mandal M, Das S et al (2003) Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253, 269-285 DOI |
4 | O-charoenrat P, Modjtahedi H, Rhys-Evans P et al (2000) Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinama cells. Cancer Res 60, 1121-1128 |
5 | Lv FZ, Wang JL, Wu Y et al (2015) Knockdown of MMP12 inhibits the growth and invasion of lung adenocarcinoma cells. Int J Immunopathol Pharmacol 28, 77-84 DOI |
6 | Flavin R, Pettersson A, Hendrickson WK et al (2014) SPINK1 protein expression and prostate cancer progression. Clin Cancer Res 20, 4904-4911 DOI |
7 | Zhang X, Yin X, Shen P et al (2017) The association between SPINK1 and clinical outcomes in patients with prostate cancer: a systematic review and meta-analysis. Onco Targets Ther 10, 3123-3130 DOI |
8 | Rasanen K, Itkonen O, Koistinen H and Stenman UH (2016) Emerging Roles of SPINK1 in Cancer. Clin Chem 62, 449-457 DOI |
9 | Paci E, Puliti D, Lopes Pegna A et al (2017) Mortality, survival and incidence rates in the ITALUNG randomized lung cancer screening trial. Thorax 72, 825-831 DOI |
10 | Parkin DM, Bray F, Ferlay J et al (2002) Global cancer statistics. CA Cancer J Clin 55, 74-108 |
11 | Stenman UH, Huhtala ML, Koistinen R et al (1982) Immunochemical demonstration of an ovarian cancer-associated urinary peptide. Int J Cancer 30, 53-57 DOI |
12 | Molina JR, Yang P, Cassivi SD et al (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83, 584-594 DOI |
13 | Stenman UH (2002) Tumor-associated trypsin inhibitor. Clin Chem 48, 1206-1209 |
14 | Itkonen O and Stenman UH (2014) TATI as a biomarker. Clin Chim Acta 431, 260-269 DOI |
15 | Scheving LA (1983) Primary amino acid sequence similarity between human epidermal growth factorurogastrone, human pancreatic secretory trypsin inhibitor, and members of porcine secretin family. Arch Biochem Biophys 226, 411-413 DOI |
16 | Ateeq B, Tomlins SA, Laxman B et al (2011) Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl 3, 72ra17 |
17 | Ida S, Ozaki N, Araki K et al (2015) SPINK1 status in colorectal cancer, impact on proliferation, and role in colitis-associated cancer. Mol Cancer Res 13, 1130-1138 DOI |
18 | Ateeq B, Tomlins SA, Laxman B et al (2011) Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 3, 72ra17 |
19 | Zhang J, Wang D, Hu N et al (2016) The construction and proliferative effects of a lentiviral vector capable of stably overexpressing SPINK1 gene in human pancreatic cancer AsPC-1 cell line. Tumour Biol 37, 5847-5855 DOI |
20 | Mehner C, Oberg AL, Kalli KR et al (2015) Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers. Oncotarget 6, 35737-35754 |
21 | Chen YT, Tsao SC, Yuan SS et al (2015) Serine protease inhibitor Kazal type 1 (SPINK1) promotes proliferation of colorectal cancer through the epidermal growth factor as a prognostic marker. Pathol Oncol Res 21, 1201-1208 DOI |
22 | El-mezayen HA, Metwally FM and Darwish H (2014) A novel discriminant score based on tumor-associated trypsin inhibitor for accurate diagnosis of metastasis in patients with breast cancer. Tumour Biol 35, 2759-2767 DOI |
23 | Ozaki N, Ohmuraya M, Hirota M et al (2009) Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor. Mol Cancer Res 7, 1572-1581 DOI |
24 | Gaber A, Johansson M, Stenman UH et al (2009) High expression of tumour associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer. Br J Cancer 100, 1540-1548 DOI |
25 | Tomlins SA, Rhodes DR, Yu J et al (2008) The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 13, 519-528 DOI |
26 | Tiwari R, Pandey SK, Goel S et al (2015) SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression. Oncogenesis 10, 4:e162 |